These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 11424231

  • 1. Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications.
    Porte D.
    Diabetes Metab Res Rev; 2001; 17(3):181-8. PubMed ID: 11424231
    [Abstract] [Full Text] [Related]

  • 2. Type II diabetes mellitus.
    Edelman SV.
    Adv Intern Med; 1998; 43():449-500. PubMed ID: 9506190
    [Abstract] [Full Text] [Related]

  • 3. The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus.
    Del Prato S, Tiengo A.
    Diabetes Metab Res Rev; 2001; 17(3):164-74. PubMed ID: 11424229
    [Abstract] [Full Text] [Related]

  • 4. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going.
    DeFronzo RA.
    Am J Med; 2010 Mar; 123(3 Suppl):S38-48. PubMed ID: 20206731
    [Abstract] [Full Text] [Related]

  • 5. Pathophysiology of type 2 diabetes: rationale for different oral antidiabetic treatment strategies.
    Giorgino F, Laviola L, Leonardini A.
    Diabetes Res Clin Pract; 2005 Jun; 68 Suppl1():S22-9. PubMed ID: 15955371
    [Abstract] [Full Text] [Related]

  • 6. Durability of glycemic control: a feature of the thiazolidinediones.
    Serdy S, Abrahamson MJ.
    Diabetes Technol Ther; 2004 Apr; 6(2):179-89. PubMed ID: 15117584
    [Abstract] [Full Text] [Related]

  • 7. Gycemic control, mealtime glucose excursions, and diabetic complications in type 2 diabetes mellitus.
    Palumbo PJ.
    Mayo Clin Proc; 2001 Jun; 76(6):609-18. PubMed ID: 11393500
    [Abstract] [Full Text] [Related]

  • 8. Treating dual defects in diabetes: insulin resistance and insulin secretion.
    Bohannon NJ.
    Am J Health Syst Pharm; 2002 Dec 01; 59 Suppl 9():S9-13. PubMed ID: 12489381
    [Abstract] [Full Text] [Related]

  • 9. Treating hyperglycemia in type 2 diabetes: new goals and strategies.
    Lebovitz HE.
    Cleve Clin J Med; 2002 Oct 01; 69(10):809-20. PubMed ID: 12371804
    [Abstract] [Full Text] [Related]

  • 10. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ, Bailey CJ.
    Drugs; 2005 Oct 01; 65(3):385-411. PubMed ID: 15669880
    [Abstract] [Full Text] [Related]

  • 11. Potential new treatments for type 2 diabetes.
    Bailey CJ.
    Trends Pharmacol Sci; 2000 Jul 01; 21(7):259-65. PubMed ID: 10871894
    [Abstract] [Full Text] [Related]

  • 12. The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents.
    Rosak C.
    J Diabetes Complications; 2002 Jul 01; 16(1):123-32. PubMed ID: 11872380
    [Abstract] [Full Text] [Related]

  • 13. Issues surrounding tight glycemic control in people with type 2 diabetes mellitus.
    Cerveny JD, Leder RD, Weart CW.
    Ann Pharmacother; 1998 Sep 01; 32(9):896-905. PubMed ID: 9762378
    [Abstract] [Full Text] [Related]

  • 14. Pharmacological interventions that directly stimulate or modulate insulin secretion from pancreatic beta-cell: implications for the treatment of type 2 diabetes.
    Farret A, Lugo-Garcia L, Galtier F, Gross R, Petit P.
    Fundam Clin Pharmacol; 2005 Dec 01; 19(6):647-56. PubMed ID: 16313276
    [Abstract] [Full Text] [Related]

  • 15. The importance of early insulin secretion and its impact on glycaemic regulation.
    Garber AJ.
    Int J Obes Relat Metab Disord; 2000 Sep 01; 24 Suppl 3():S32-7. PubMed ID: 11063282
    [Abstract] [Full Text] [Related]

  • 16. Improving glycaemic control with current therapies.
    Birkeland KI.
    Diabet Med; 1998 Sep 01; 15 Suppl 4():S13-9. PubMed ID: 9868986
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological management of type 2 diabetes mellitus: rationale for rational use of insulin.
    Chan JL, Abrahamson MJ.
    Mayo Clin Proc; 2003 Apr 01; 78(4):459-67. PubMed ID: 12683698
    [Abstract] [Full Text] [Related]

  • 18. The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type II diabetes mellitus.
    Standl E, Füchtenbusch M.
    Diabetologia; 2003 Mar 01; 46 Suppl 1():M30-6. PubMed ID: 12652356
    [Abstract] [Full Text] [Related]

  • 19. Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test.
    Festa A, Williams K, Hanley AJ, Haffner SM.
    Diabetes; 2008 Jun 01; 57(6):1638-44. PubMed ID: 18332099
    [Abstract] [Full Text] [Related]

  • 20. Insulin resistance as the core defect in type 2 diabetes mellitus.
    Goldstein BJ.
    Am J Cardiol; 2002 Sep 05; 90(5A):3G-10G. PubMed ID: 12231073
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.